Navigation Links
Pancreas-targeted siRNA In Vivo Transfection Kit from Altogen Biosystems
Date:3/6/2012

LAS VEGAS, March 6, 2012 /PRNewswire/ -- Altogen Biosystems announced the launch of its new pancreas-targeted in vivo RNAi transfection system in the company's popular in vivo delivery product line for use in laboratories and research facilities for development of new medicines and testing in cells and animals. This in vivo reagent is designed for targeted siRNA delivery into pancreas, however it is also compatible for transfection of any negatively charged molecules including RNA, DNA, proteins, and small molecules.

The pancreas is very important hormone-secreting organ in the human body. Pancreatic diseases include: Diabetes, pancreatitis, cystic fibrosis, and neoplasms. Pancreatic cancer is the fourth leading cause of cancer death in the United States with a lowest survival rate of its victims than any other form of cancer. Researchers in diabetes, pancreatic cancer, and other pancreas disorders, are focused on discovering and developing new therapeutics for patients. Testing novel compounds require efficient and targeted delivery of pharmaceuticals into pancreas tissue (known as in vivo transfection).

Pancreas-targeted siRNA In Vivo Transfection Kit enables researchers to utilize in vivo transfection method to introduce DNA, RNA, and other molecules into pancreas cells. This liposome-based technology makes it possible to cross the cellular barriers and deliver genetic material, or a small interfering RNA (siRNA) into the cells for research or therapeutic purposes.  Highly efficient targeted delivery of biomolec
'/>"/>

SOURCE Altogen Biosystems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Silence Therapeutics Signs siRNA Delivery Collaboration With Top 10 Pharma Company
2. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
3. Sirnaomics Seals a Second Partnership Deal with a Chinese Pharmaceutical Company for Developing siRNA Therapeutics
4. Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007
5. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
6. Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
7. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
8. Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials
9. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
10. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
11. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announces ... June 4 at 1:00 p.m. ET / 10:00 a.m. ... Internet.  Simply log onto our website listed above. If ... a replay of the webcast will be available for ... ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting its leadership ...
(Date:5/28/2015)... , May 28, 2015  CytomX, a biotechnology company ... announced that Sean McCarthy , D. Phil., chief ... 2015 Global Healthcare Conference in New ... June 2, 2015. Dr. McCarthy will provide an overview ... immunotherapy and Probody drug conjugate programs. About ...
(Date:5/28/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report  "Personalized Medicine ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The aim ... to match the right drug to the ... to design the appropriate treatment for a ...
Breaking Medicine Technology:Webcast Alert: Akcea Therapeutics Conference Call 2Webcast Alert: Akcea Therapeutics Conference Call 3Global Personalized Medicine Report 2015-2024 - Scientific and Commercial Aspects 2Global Personalized Medicine Report 2015-2024 - Scientific and Commercial Aspects 3
... 1, 2011 /PRNewswire-USNewswire/ – CoMeD – On ... Programme (UNEP) distributed a revised text for ... mercury-free drugs were gratified to see pharmaceuticals listed in ... treaty. The Coalition for Mercury-free Drugs ...
... Reportlinker.com announces that a new market research ... Dry Powder Inhalation: Devices, Drugs, ... http://www.reportlinker.com/p0581176/Dry-Powder-Inhalation-Devices-Drugs-Therapeutics-Markets-and-Forecasts .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ... device design are creating new opportunities for ...
Cached Medicine Technology:Global Mercury Treaty May Include Ban on Mercury in Medicine 2Global Mercury Treaty May Include Ban on Mercury in Medicine 3Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts 2Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts 3
(Date:5/29/2015)... The world of dentistry had an image problem in ... who dispense pain to people unfortunate enough to need to ... came to surgeries, people would have to spend a lot ... back in the 20th Century now. Nowadays one need only ... Sheepshead Bay neighborhood of Brooklyn, New York to see ...
(Date:5/29/2015)... The 3D Certificate program is for senior managers, ... and engineering aspects of evaluating 3D technology. Any company ... in their existing 3D investment, or getting an education ... in manufacturing in various fields, will benefit greatly from ... that cover the following topics: state of the art ...
(Date:5/29/2015)... 2015 Acoustiblok recently resolved a noisy ... for Three Valleys Municipal Water District (Three Valleys MWD) ... working on the project said, “The new Acoustiblok All ... and are much better looking than the temporary barriers. ... helped us throughout the process, and the customer service ...
(Date:5/28/2015)... 29, 2015 Medical Device Cybersecurity ... Approaches, **FDAnews Webinar**, June 23, 2015 — 1:00 ... , Network connectivity opens up a wealth of ... a minefield of potential liabilities. Devices transmit data ... can manufacturers be sure the information doesn’t fall ...
(Date:5/28/2015)... 28, 2015 Today the National Resident ... for the 2015 Main Residency Match®. A record-number ... were filled when the matching algorithm was processed. ... during the Match Week Supplemental Offer and Acceptance Program® ... are pleased with the outcome of the 2015 Main ...
Breaking Medicine News(10 mins):Health News:Brooklyn Dentist Delivers Comfortable Care Through High Technology 2Health News:Brooklyn Dentist Delivers Comfortable Care Through High Technology 3Health News:Brooklyn Dentist Delivers Comfortable Care Through High Technology 4Health News:Second Cohort in 3D Certificate Program to Launch in August by Graduate School 2Health News:Second Cohort in 3D Certificate Program to Launch in August by Graduate School 3Health News:Acoustiblok® Quiets Well Motor Noise for California Water District 2Health News:Acoustiblok® Quiets Well Motor Noise for California Water District 3Health News:Acoustiblok® Quiets Well Motor Noise for California Water District 4Health News:Acoustiblok® Quiets Well Motor Noise for California Water District 5Health News:FDAnews Announces — Medical Device Cybersecurity Quality Assurance: Requirements, Best Practices and Innovative Approaches Webinar, June 23, 2015 2Health News:FDAnews Announces — Medical Device Cybersecurity Quality Assurance: Requirements, Best Practices and Innovative Approaches Webinar, June 23, 2015 3Health News:NRMP Releases Results and Data: 2015 Residency Match: Record Number of Positions Filled 2Health News:NRMP Releases Results and Data: 2015 Residency Match: Record Number of Positions Filled 3
... 24th January 2008 - The main regulators of the ... highly involved in a large range of immune diseases. ... play a critical role in the onset of type ... Dr. Ciriaco Piccirillo, a researcher in the Department of ...
... new treatments for diabetes, researchers say , , THURSDAY, Jan. 24 ... managed to locate stem cells in the pancreas -- in ... in humans, they could pave the way for dramatic new ... the body could once again produce its own insulin. Until ...
... of consumer statutes, breach of warranty and, unjust enrichment; Damages ... of $5 billion last year, mostly paid through Medicare, Medicaid, ... other federal drug programs and private insurance, JACKSONVILLE, Fla., ... announced that they have filed a lawsuit against,Merck & Company ...
... ... to Your Neighborhood, WASHINGTON, Jan. 24 The national nonprofit,Home ... home safety exhibit -- The Great Safety Adventure.,In an effort to ... been touring the country since 1999 stopping at,elementary schools and Lowe,s ...
... During Super Bowl, WASHINGTON, Jan. 24 ... (ONDCP) is launching its first major,Federal effort to ... public awareness campaign will begin with advertising during ... TV advertising targeting,parents in nearly two years. The ...
... ... a healthy lifestyle, NEW YORK, Jan. 24 Aflac (NYSE: ... Girl. With 10 events nationwide, ranging,from 5K/10K, duathlon and triathlons, Aflac ... active lifestyle., To illustrate the collective commitment to this partnership, ...
Cached Medicine News:Health News:Deficient regulators in the immune system responsible for type 1 diabetes 2Health News:Stem Cells Finally Found in Pancreas 2Health News:Stem Cells Finally Found in Pancreas 3Health News:Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough 2Health News:Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough 3Health News:The Great Safety Adventure(R) Traveling Home Safety Exhibit Kicks Off Tenth Anniversary Tour 2Health News:The Great Safety Adventure(R) Traveling Home Safety Exhibit Kicks Off Tenth Anniversary Tour 3Health News:ONDCP Launches First Major Initiative to Combat Teen Prescription Drug Abuse 2Health News:ONDCP Launches First Major Initiative to Combat Teen Prescription Drug Abuse 3Health News:ONDCP Launches First Major Initiative to Combat Teen Prescription Drug Abuse 4Health News:Aflac to Sponsor Iron Girl 2Health News:Aflac to Sponsor Iron Girl 3
Lyphochek Benzo/TCA Control Set A is ideal for monitoring HPLC methods for identification and quantitation of benzodiazepines and tricyclic antidepressant drugs....
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis....
Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
qUAntify Plus Control is a combination urine dipstick and microscopic control. The control is available in either 12 mL centrifuge tubes or 120 mL flip-top squeeze bottles....
Medicine Products: